Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. West Pharmaceutical Services Inc. shares valued at $4,836,074 were sold by Birkett Bernard on Aug 02. At $341.19 per share, Birkett Bernard sold 14,174 shares. The insider’s holdings dropped to 795 shares worth approximately $0.17 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Abraham Silji sold 5,374 shares, netting a total of over 1,848,306 in proceeds. Following the sale of shares at $343.93 each, the insider now holds 3,201 shares.
Before that, Lai Quintin J had sold 8,016 shares from its account. In a trade valued at $2,979,492, the VP Corp Development & Strategy traded West Pharmaceutical Services Inc. shares for $371.69 each. Upon closing the transaction, the insider’s holdings decreased to 8,016 shares, worth approximately $1.12 million.
As published in a research note from BofA Securities on October 28, 2022, West Pharmaceutical Services Inc. [WST] has been rated down from a Buy to a Neutral and the price target has been revised to $250 from $385. This represents a 16.26% premium over Thursday’s closing price. Analysts at KeyBanc Capital Markets started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. As of October 14, 2020, Stephens has initiated its “an Equal-weight” rating for WST. Earlier on July 21, 2020, BofA Securities upgraded its rating. Their new recommendation was “a Buy” for WST stock which previously was a “a Neutral”.
Analyzing WST Stock Performance
On Thursday, West Pharmaceutical Services Inc. [NYSE: WST] plunged -4.64% to $209.34. The stock’s lowest price that day was $208.79, but it reached a high of $215.10 in the same session. During the last five days, there has been a drop of approximately -5.37%. Over the course of the year, West Pharmaceutical Services Inc. shares have dropped approximately -55.37%. Shares of the company reached a 52-week high of $468.05 on 01/03/22 and a 52-week low of $206.19 on 10/27/22. A 50-day SMA is recorded $262.05, while a 200-day SMA reached $324.85. Nevertheless, trading volume fell to 1.07 million shares from 0.95 million shares the previous day.
Support And Resistance Levels for West Pharmaceutical Services Inc. (WST)
According to the 24-hour chart, there is a support level at 207.05, which, if violated, would cause prices to drop to 204.77. In the upper region, resistance lies at 213.36. The next price resistance is at 217.39. RSI (Relative Strength Index) is 33.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -16.27, which suggests the price will decrease in the coming days. Percent R is at 94.62%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is West Pharmaceutical Services Inc. subject to short interest?
Stocks of West Pharmaceutical Services Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.2 million shares to 0.96 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 0.76 million shares. A jump of 20.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.09 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.09.
Which companies own the most shares of West Pharmaceutical Services Inc. (WST)?
According to The Vanguard Group, Inc. filings, the company currently owns 8,527,649 shares, which is about 11.52% of the total WST shares outstanding. The investor’s shares have appreciated by 110,885 from its previous 13-F filing of 8416764.0 shares. With the completion of the sale transaction, T. Rowe Price Associates, Inc.’s stake is now worth $1,537,402,764. BlackRock Fund Advisors reduced a -4.22% interest valued at $1.08 billion while SSgA Funds Management, Inc. sold a -70,198 stake. A total of -18,688 shares of West Pharmaceutical Services Inc. were sold by Franklin Advisers, Inc. during the quarter, and -137,599 were sold by APG Asset Management NV. In its current portfolio, Fidelity Management & Research Co holds 1,828,105 shares valued at $449.86 million.
In terms of West Pharmaceutical Services Inc. share price expectations, FactSet research, analysts set an average price target of $295.00 in the next 12 months, up nearly 18.43% from the previous closing price of $219.53. Analysts anticipate West Pharmaceutical Services Inc. stock to reach $449.00 by 2022, with the lowest price target being $206.00. In spite of this, 9 analysts ranked West Pharmaceutical Services Inc. stock as an Overweight at the end of 2022. On April 24, 2020, BofA/Merrill assigned a price target of “a Neutral” to the stock and upgraded coverage with a $200.